Table 5.

Antineoplastic agents used in patients treated in the clinical trial setting in 2010 and 2019.

2010			2019
Antineoplastic Agent	Expenditure	% of Total Expenditure	Antineoplastic Agent	Expenditure	% of Total Expenditure
Trastuzumab	EUR 919,484	37.4	Pembrolizumab	EUR 3,590,128.10	13.0
Bevacizumab	EUR 449,063	18.3	Nivolumab	EUR 2,489,205.42	9.0
Aflibercept/placebo	EUR 301,600	12.3	Cabozantinib	EUR 2,392,934.10	8.7
Docetaxel	EUR 191,287	7.8	Atezolizumab	EUR 1,983,242.04	7.2
Pemetrexed	EUR 145,919	5.9	Bevacizumab	EUR 1,696,849.55	6.1
Cetuximab	EUR 145,079	5.9	Palbociclib	EUR 1,449,416.28	5.3
Panitumumab	EUR 129,287	5.3	Olaparib	EUR 1,338,767.04	4.9
Total		92.8	Lorlatinib	EUR 1,094,262.59	4.0
			Ipilumumab	EUR 786,563.46	2.8
			Pembrolizumab	EUR 670,891,67	2.4
			Pemetrexed	EUR 615,425.91	2.2
			Pertuzumab	EUR 581,406.00	2.1
			Avelumab	EUR 568,416.00	2.1
			Abiraterone	EUR 500,524.62	1.8
			Pembrolizumab/placebo	EUR 405,841.74	1.5
			Cetuximab	EUR 393,887.10	1.4
			Lenvatinib	EUR 386,416.81	1.4
			Dinutuximab	EUR 348,727.07	1.3
			Atezolizumab/placebo	EUR 326,070.63	1.2
			Osimertinib	EUR 300,501.60	1.1
			Sunitinib	EUR 299,647.57	1.1
			BMS-986213/Nivolumab	EUR 289,906.56	1.0
			Axitinib	EUR 280,783.80	1.0
			Enzalutamide	EUR 274,394.96	1.0
			Trastuzumab s.c.	EUR 271,830.00	1.0
			Apalutamide	EUR 259,110.00	0.9
			Ipilimumab/placebo	EUR 222,314.53	0.8
			Trastuzumab	EUR 217,028.66	0.8
			Alectinib	EUR 204,001.91	0.7
			Panitumumab	EUR 183,674.66	0.7
			Nivolumab/placebo	EUR 183,520.80	0.7
			Niraparib	EUR 181,838.25	0.7
			Olaratumab/placebo	EUR 181,812.21	0.7
			Total		90.6